Orphanet Journal of Rare Diseases
Scope & Guideline
Fostering collaboration in the rare disease community.
Introduction
Aims and Scopes
- Clinical Research on Rare Diseases:
This includes studies that explore clinical presentations, treatment efficacy, and long-term outcomes of various rare diseases, contributing to improved management and care protocols. - Genetic Characterization and Genomics:
The journal emphasizes studies that delve into the genetic underpinnings of rare diseases, including mutation analysis, genotype-phenotype correlations, and the use of next-generation sequencing to enhance diagnostic accuracy. - Patient-Centered Outcomes and Quality of Life:
Research focusing on patient-reported outcomes, quality of life assessments, and the psychosocial impact of rare diseases on patients and their families is a core area, highlighting the importance of patient perspectives in treatment planning. - Health Economics and Burden of Illness:
The journal publishes studies that assess the economic impact of rare diseases, including cost-of-illness analyses and healthcare utilization, providing insights into the broader implications of these conditions on healthcare systems. - Innovative Therapeutics and Treatment Approaches:
Research on novel therapeutic interventions, including pharmacological treatments, gene therapies, and clinical trial methodologies to evaluate the effectiveness of new therapies for rare diseases. - Multidisciplinary and Collaborative Approaches:
The journal promotes interdisciplinary research that involves collaboration among clinicians, researchers, and patients, fostering a holistic approach to the study and management of rare diseases.
Trending and Emerging
- Telemedicine and Remote Care:
The COVID-19 pandemic has accelerated interest in telehealth solutions for managing rare diseases, leading to an increase in studies examining the effectiveness of remote consultations and digital health technologies. - Patient Engagement and Advocacy:
There is a growing focus on the role of patient advocacy groups and their influence on research priorities and treatment development, highlighting the importance of patient voices in shaping healthcare policies. - Longitudinal and Natural History Studies:
Research tracking the long-term progression of rare diseases is gaining traction, aiming to improve understanding of disease trajectories and inform future therapeutic strategies. - Integration of Artificial Intelligence in Rare Disease Research:
The application of AI and machine learning in analyzing large datasets for rare diseases is emerging, with studies exploring how these technologies can enhance diagnostics and treatment personalization. - Health Disparities in Rare Diseases:
An increasing emphasis on understanding the disparities in access to care and treatment outcomes among different populations affected by rare diseases is becoming more prevalent.
Declining or Waning
- Epidemiological Studies of Rare Diseases:
There has been a noticeable decline in publications solely focused on the epidemiology of rare diseases, possibly due to the increasing integration of epidemiological data into broader studies that also consider genetic and clinical aspects. - Traditional Case Reports:
The frequency of traditional case reports has diminished as the journal increasingly emphasizes systematic reviews and larger cohort studies that provide more comprehensive data. - Single-Country Focused Studies:
Research that concentrates on rare diseases within a specific country is becoming less common, as there is a growing trend toward multi-national studies that provide a more global perspective on rare diseases.
Similar Journals
European Journal of Medical Genetics
Bridging Laboratory Discoveries with Clinical PracticeEuropean Journal of Medical Genetics, published by Elsevier, is a pivotal platform dedicated to advancing knowledge in the fields of medical genetics and its clinical applications. With an ISSN of 1769-7212 and an E-ISSN of 1878-0849, this journal fosters innovative research and insights into the genetic factors that influence human health. Ranked in the Q3 category for both Genetics and Clinical Genetics, and achieving notable recognition in Medicine (miscellaneous) with a Q2 positioning, it strives to bridge the gap between laboratory findings and clinical practice. Operating in an Open Access format, the journal aims at maximally disseminating essential findings to researchers, professionals, and students alike, ensuring that critical advances in genetics are accessible to the global medical community. With converged publication years spanning from 2005 to 2024, the journal strengthens its mission to be at the forefront of genetic research that informs clinical methodologies and fosters improved healthcare outcomes.
ORVOSI HETILAP
Fostering Interdisciplinary Insights in HealthcareORVOSI HETILAP is a pivotal journal in the field of general medicine, published by AKADEMIAI KIADO ZRT in Hungary. With its rich history dating back to 1949, this journal has been a platform for disseminating significant research findings and clinical advancements that impact healthcare practices. Although it currently falls within the Q4 category in the 2023 ranking of Medicine (miscellaneous), it holds a Scopus rank of #320 among 636 journals in its category, indicating its growing recognition among peers and scholars. The journal does not offer open access options, which may limit broader dissemination, but it nonetheless remains an important resource for medical professionals, researchers, and students engaging with contemporary medical issues. Located in the vibrant academic landscape of Budapest, ORVOSI HETILAP continues to contribute to the evolving dialogue in the medical community, showcasing diverse topics and fostering interdisciplinary collaboration.
Clinical Medicine & Research
Advancing clinical excellence through innovative research.Clinical Medicine & Research is a premier peer-reviewed journal published by Marshfield Clinic, dedicated to advancing the field of medical science with a focus on clinical and community-based care. Established in 2003, the journal showcases groundbreaking research and innovative practices aimed at improving patient outcomes and optimizing healthcare delivery. With an ISSN of 1539-4182 and an E-ISSN of 1554-6179, it has garnered recognition in the academic community, achieving a Q2 ranking in Community and Home Care and a Q3 ranking in Miscellaneous Medicine categories as of 2023. The journal’s Scopus rankings further emphasize its relevance, placing it at #263 in General Medicine and #20 in Community and Home Care. Although it operates under a subscription model, Clinical Medicine & Research remains pivotal for researchers, professionals, and students seeking to stay informed about the latest advancements in clinical practice and healthcare methodologies, with an eye toward its impact on the broader medical landscape through 2024 and beyond.
Reumatologia Clinica
Advancing rheumatologic research for a healthier future.Reumatologia Clinica is a distinguished journal dedicated to the field of Rheumatology, published by Elsevier España SLU. With its ISSN of 1699-258X and E-ISSN 1885-1398, the journal aims to disseminate pivotal research findings and clinical studies from 2005 to 2024, spotlighting advancements in the understanding and treatment of rheumatic diseases. Based in Barcelona, Spain, it plays a vital role in the academic community, ranking in the Q3 category for Rheumatology as of 2023, with a Scopus ranking of #44 out of 73, placing it in the 40th percentile. Although it operates under a traditional access model, the journal is committed to academic excellence, providing researchers, healthcare professionals, and students with invaluable insights that drive the field forward. Reumatologia Clinica serves as an essential resource for those looking to deepen their knowledge and contribute to the evolving landscape of rheumatologic research.
ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE
Advancing Dermatological Knowledge Since 1977ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE is a distinguished journal that serves as a vital platform for disseminating innovative research and insightful reviews in the field of dermatology and venereology. Published by MASSON EDITEUR, this journal has been a cornerstone for professionals and researchers since its inception in 1977, offering a wealth of knowledge that spans decades. With its ISSN 0151-9638 and E-ISSN 2214-5451, it is indexed within leading databases, ensuring that the published work reaches a broad audience. The journal currently holds a Q3 ranking in the dermatology category, reflecting its commitment to quality and rigorous peer-review processes. While the journal is not open access, it provides an extensive archive of valuable studies that contribute to advancements in skin health and treatment methodologies. Located in Issy-les-Moulineaux, France, ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE continues to attract submissions from esteemed professionals, enhancing its reputation as a crucial resource for those dedicated to the ongoing development of dermatological sciences.
Case Reports in Oncological Medicine
Empowering healthcare professionals with valuable case reports.Case Reports in Oncological Medicine is a distinguished open-access journal published by HINDAWI LTD, dedicated to disseminating valuable insights and findings in the field of oncology. Since its inception in 2011, this journal has aimed to provide a unique platform for the publication of detailed case reports that contribute to our understanding of cancer diagnosis, treatment, and management. With a specific focus on sharing clinical experiences and outcomes, it seeks to engage researchers, healthcare professionals, and students who are committed to advancing oncological knowledge and improving patient care. Although coverage in Scopus was discontinued from 2014 to 2017, the journal currently holds a rank of #232/323 in Medicine - Oncology, placing it within the 28th percentile. Researchers interested in making their work accessible can benefit from the journal's open-access model, allowing greater visibility and citation potential within the scientific community. The journal is positioned as an important resource for those looking to stay updated on the latest case studies and innovations in oncological medicine.
RMD Open
Pioneering open-access research in rheumatic diseases.RMD Open, published by the BMJ Publishing Group, is a leading open-access journal that has made significant contributions to the fields of Immunology, Immunology and Allergy, and Rheumatology since its inception in 2015. With an impressive Q1 ranking in these categories for 2023, the journal has established itself as an essential platform for the dissemination of high-quality research, case studies, and reviews that advance understanding and treatment strategies in these critical areas of health. As an open-access publication, RMD Open ensures that its content is freely accessible to a global audience, promoting collaboration and knowledge sharing among researchers, clinicians, and students. Based in the United Kingdom at the British Medical Association House, RMD Open is not only dedicated to improving patient care but also to fostering innovative research and discussions in the rapidly evolving landscape of rheumatic diseases.
Journal of Istanbul Faculty of Medicine-Istanbul Tip Fakultesi Dergisi
Bridging ideas and innovation in the medical community.The Journal of Istanbul Faculty of Medicine (Istanbul Tip Fakultesi Dergisi), published by ISTANBUL UNIVERSITY, FACULTY OF MEDICINE, is an esteemed open-access journal that has been committed to disseminating significant medical research since becoming open access in 2017. As a platform for transformative scholarly work, this journal is situated in Turkey and actively engages with diverse medical disciplines to contribute to the collective understanding of health and medicine. Featuring a range of studies that span various facets of medical science, the journal is categorized within the Q4 quartile in Medicine (miscellaneous) for 2023, with its Scopus rankings placing it at #586 out of 636 in the General Medicine category, marking it as a resource that is gaining traction within the academic community. This journal aims to serve as a vital resource for researchers, healthcare professionals, and students alike, fostering the exchange of ideas and innovation in medicine. By providing public access to its content, it underscores the importance of open science in enhancing knowledge sharing and collaboration across borders. For those interested in advancing their research and professional development, the Journal of Istanbul Faculty of Medicine is an invaluable tool for staying informed on the latest findings and discussions in the medical field.
Open Access Rheumatology-Research and Reviews
Empowering Researchers with Open Access Insights.Open Access Rheumatology-Research and Reviews, published by DOVE MEDICAL PRESS LTD, is a distinguished journal that has been a vital part of the rheumatology field since its inception in 2009. With an ISSN of 1179-156X, this journal is dedicated to disseminating groundbreaking research and comprehensive reviews in the discipline of rheumatology, making it an essential resource for researchers, clinicians, and students alike. It boasts an impressive Q3 ranking in the Rheumatology category for 2023, reflecting its relevance and quality within a highly competitive landscape, where it ranks in the 51st percentile among its peers as indicated by the Scopus Ranks. As an open-access platform, it ensures that critical findings and insights are easily accessible to a global audience, promoting collaboration and knowledge sharing. The journal's scope includes a wide range of topics within rheumatology, aimed at advancing understanding and treatment of musculoskeletal disorders and autoimmune diseases. Its headquarters is located in New Zealand, positioning it as a key player in the international research community.
Expert Opinion on Orphan Drugs
Navigating the complexities of rare disease treatments.Expert Opinion on Orphan Drugs is a pivotal academic journal published by Taylor & Francis Ltd, focusing on the burgeoning field of orphan drugs, which are often essential for treating rare diseases. As an integral source of insights and advancements from 2013 to 2024, this journal aims to bridge the gap between emerging scientific research and clinical application, providing a platform for authors to discuss pharmacological innovations and policy implications. With its ISSN 2167-8707, the journal has established a reputably rigorous editorial process and is indexed in Scopus, showcasing its relevance with ranks in various pharmacology and health policy disciplines. Though currently not an open-access journal, it endeavors to deliver high-quality articles that are vital for researchers, healthcare professionals, and policy makers aiming to navigate the complexities and challenges in the orphan drug landscape. It is categorized in Q4 for Health Policy and Q3 for Pharmacology in recent evaluations, reflecting its accessible yet scholarly contributions to this niche area of medical research.